Bio-Rad Laboratories, Inc. · NYSE:BIO
Bio-Rad Laboratories — Q3 2026 Earnings Presentation
16 slides from Bio-Rad Laboratories's earnings presentation, Nov 4, 2026
Slide 1: Third Quarter 2026 Financial Results
Third Quarter 2026 Financial Results Supplemental Earnings Results Presentation November 4, 2026
Slide 2: Safe Harbor
Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future
Slide 3: Q3 2026 GAAP Financial Results
Q3 2026 GAAP Financial Results Revenue Gross Operating Net Cash From Margin Margin* Operations $656M 50.1% (7.6)% $96M Change 0.5% As Reported -250 bps -1,760 bps -$25M YoY 0.7% CN** * Operating Margin of (7.6)% includes restructuring charges of approximately $77 million and a non-cash impairment ch
Slide 4: Q3 2026 Non-GAAP Financial Results
Q3 2026 Non-GAAP Financial Results Revenue Gross Operating Free Cash Margin* Margin* Flow* $656M 54.5% 12.8% $65M Change 0.5% As Reported +100 bps +100 bps -$24M YoY 0.7% CN** * Reconciliations to the comparable GAAP measure for the non-GAAP items shown above are detailed in the reconciliation table
Slide 5: Q3 2026 Business Segment Revenue and Geographic Mix
Q3 2026 Business Segment Revenue and Geographic Mix Revenue by Business Revenue by Geography Segment APAC 21% EMEA Life Science 34% 39% $656M $656M Clinical Diagnostics 61% Americas 45% 5 Our Mission: Advance Science and Save Lives, Together
Slide 6: Life Science Segment
Life Science Segment Revenue by Geography Q3 2026 Revenue $255M APAC -2.8% YoY 20% -2.4% YoY CN* EMEA 33% • Life Science segment revenue decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific.* • Excluding Process Chromatography, revenue grew 2.5%.* • Droplet Digital
Slide 7: Clinical Diagnostics Segment
Clinical Diagnostics Segment Revenue by Geography Q3 2026 Revenue $402M APAC 22% +2.7% YoY EMEA +2.8% YoY CN* 34% • Clinical Diagnostics segment revenue increased in the Americas and Asia Pacific, partially offset by decreased sales in EMEA.* • Growth led by quality systems and diabetes products.* A
Slide 8: Balance Sheet Highlights
Balance Sheet Highlights September 30, 2026 December 31, 2025 (In $ millions) (In $ millions) Cash & Short-Term Investments $1,664 $1,541 Long-Term Debt, including current maturities $1,204 $1,203 Inventories, net $784 $741 Investment in Sartorius AG $5,849 $5,669 8 Our Mission: Advance Science and
Slide 9: Full-Year 2026 Outlook
Full-Year 2026 Outlook Revenue CN* YoY Growth -3.0% to +0.5% Life Science Revenue CN* YoY -3.0% to -1.0% Clinical Diagnostics Revenue CN* YoY -3.0% to +1.0% Non-GAAP Gross Margin** 53.0% to 54.0% Non-GAAP Operating Margin** 10.0% to 12.0% Free Cash Flow** $290M to $340M * Currency Neutral Revenue: W
Slide 10: Appendix: Use of Non-GAAP Financial Measures
Appendix Use of Non-GAAP Financial Measures This presentation includes GAAP financial measures as well as non-GAAP financial measures, which are not meant to be considered in isolation or as a substitute for comparable GAAP measures. We present certain non-GAAP financial measures to evaluate busines
Slide 11: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures 11 Our Mission: Advance Science and Save Lives, Together
Slide 12: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued) 12 Our Mission: Advance Science and Save Lives, Together
Slide 13: Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued)
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (continued) 13 Our Mission: Advance Science and Save Lives, Together
Slide 14: Explanations of Non-GAAP Adjustments
Explanations of Non-GAAP Adjustments Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of amortization can vary significantly and are unique to each acquisit
Slide 15: Other Key Metrics
Other Key Metrics Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for acquisitions and other investing and financing activities. The company also uses this measure as a
Slide 16: 2026 Financial Outlook
2026 Financial Outlook Forecasted non-GAAP operating margin excludes 83 basis points related to amortization of purchase intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effe